MicroRNAs and polycystic kidney disease
Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicat...
Gespeichert in:
Veröffentlicht in: | Drug discovery today. Disease models 2013, Vol.10 (3), p.e137-e143 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e143 |
---|---|
container_issue | 3 |
container_start_page | e137 |
container_title | Drug discovery today. Disease models |
container_volume | 10 |
creator | Noureddine, Lama Hajarnis, Sachin Patel, Vishal |
description | Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD. |
doi_str_mv | 10.1016/j.ddmod.2013.10.001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4159181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1740675713000145</els_id><sourcerecordid>1826601583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbK3-AkF600vjzn5kNweFUvyCqiB6XpLdiW5Nk5pNC_33praWevE0w8w77zs8hJwCjYBCfDmJnJtWLmIUeDuJKIU90gUl6CBWUu3v9B1yFMKEUi4Srg5Jh0nGIKaqS84fva2rl6dh6Kel68-qYmmXofG2_-ldicu-8wHTgMfkIE-LgCeb2iNvtzevo_vB-PnuYTQcD6wQAgY6ZyqRcZYnEpjgTtOca0W1yJNYoZYpuJyDVUxq1FRRwUTm0GVUxZLp3PIeuV77zubZFJ3FsqnTwsxqP03rpalSb_5uSv9h3quFESAT0NAaXGwM6uprjqExUx8sFkVaYjUPBjSLYwpS81bK19KWQAg15tsYoGaF2EzMD2KzQrwatojbq7PdD7c3v0xbwdVagC2nhcfaBOuxtOh8jbYxrvL_BnwDGcSMdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826601583</pqid></control><display><type>article</type><title>MicroRNAs and polycystic kidney disease</title><source>Elsevier ScienceDirect Journals</source><creator>Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal</creator><creatorcontrib>Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal</creatorcontrib><description>Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.</description><identifier>ISSN: 1740-6757</identifier><identifier>EISSN: 1740-6757</identifier><identifier>DOI: 10.1016/j.ddmod.2013.10.001</identifier><identifier>PMID: 25221607</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><ispartof>Drug discovery today. Disease models, 2013, Vol.10 (3), p.e137-e143</ispartof><rights>2013 Elsevier Ltd</rights><rights>2013 Elsevier Ltd. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</citedby><cites>FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1740675713000145$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25221607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noureddine, Lama</creatorcontrib><creatorcontrib>Hajarnis, Sachin</creatorcontrib><creatorcontrib>Patel, Vishal</creatorcontrib><title>MicroRNAs and polycystic kidney disease</title><title>Drug discovery today. Disease models</title><addtitle>Drug Discov Today Dis Models</addtitle><description>Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.</description><issn>1740-6757</issn><issn>1740-6757</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AQhhdRbK3-AkF600vjzn5kNweFUvyCqiB6XpLdiW5Nk5pNC_33praWevE0w8w77zs8hJwCjYBCfDmJnJtWLmIUeDuJKIU90gUl6CBWUu3v9B1yFMKEUi4Srg5Jh0nGIKaqS84fva2rl6dh6Kel68-qYmmXofG2_-ldicu-8wHTgMfkIE-LgCeb2iNvtzevo_vB-PnuYTQcD6wQAgY6ZyqRcZYnEpjgTtOca0W1yJNYoZYpuJyDVUxq1FRRwUTm0GVUxZLp3PIeuV77zubZFJ3FsqnTwsxqP03rpalSb_5uSv9h3quFESAT0NAaXGwM6uprjqExUx8sFkVaYjUPBjSLYwpS81bK19KWQAg15tsYoGaF2EzMD2KzQrwatojbq7PdD7c3v0xbwdVagC2nhcfaBOuxtOh8jbYxrvL_BnwDGcSMdQ</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Noureddine, Lama</creator><creator>Hajarnis, Sachin</creator><creator>Patel, Vishal</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2013</creationdate><title>MicroRNAs and polycystic kidney disease</title><author>Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noureddine, Lama</creatorcontrib><creatorcontrib>Hajarnis, Sachin</creatorcontrib><creatorcontrib>Patel, Vishal</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug discovery today. Disease models</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noureddine, Lama</au><au>Hajarnis, Sachin</au><au>Patel, Vishal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNAs and polycystic kidney disease</atitle><jtitle>Drug discovery today. Disease models</jtitle><addtitle>Drug Discov Today Dis Models</addtitle><date>2013</date><risdate>2013</risdate><volume>10</volume><issue>3</issue><spage>e137</spage><epage>e143</epage><pages>e137-e143</pages><issn>1740-6757</issn><eissn>1740-6757</eissn><abstract>Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25221607</pmid><doi>10.1016/j.ddmod.2013.10.001</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1740-6757 |
ispartof | Drug discovery today. Disease models, 2013, Vol.10 (3), p.e137-e143 |
issn | 1740-6757 1740-6757 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4159181 |
source | Elsevier ScienceDirect Journals |
title | MicroRNAs and polycystic kidney disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T23%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNAs%20and%20polycystic%20kidney%20disease&rft.jtitle=Drug%20discovery%20today.%20Disease%20models&rft.au=Noureddine,%20Lama&rft.date=2013&rft.volume=10&rft.issue=3&rft.spage=e137&rft.epage=e143&rft.pages=e137-e143&rft.issn=1740-6757&rft.eissn=1740-6757&rft_id=info:doi/10.1016/j.ddmod.2013.10.001&rft_dat=%3Cproquest_pubme%3E1826601583%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826601583&rft_id=info:pmid/25221607&rft_els_id=S1740675713000145&rfr_iscdi=true |